Wuhan Hiteck Biological Pharma Co., Ltd. reported earnings results for the nine months ended September 30, 2021. For the nine months, the company reported sales was CNY 392.37 million compared to CNY 348.59 million a year ago. Revenue was CNY 392.37 million compared to CNY 348.59 million a year ago. Net income was CNY 18.64 million compared to net loss of CNY 10.53 million a year ago. Basic earnings per share from continuing operations was CNY 0.18 compared to basic loss per share from continuing operations of CNY 0.1 a year ago. Diluted earnings per share from continuing operations was CNY 0.18 compared to diluted loss per share from continuing operations of CNY 0.1 a year ago.